AABB Conducting Survey of Transfusion Practices for Patients Taking Therapeutic Monoclonal Antibodies

AABB is conducting a survey to better understand the experiences of transfusion services and immunohematology reference laboratories (IRLs) with managing patients treated with therapeutic monoclonal antibodies (mAbs) such as daratumumab (Darzalex, anti-CD38) and magrolimab (anti-CD47).

The survey will evaluate how transfusion services and IRLs are addressing problems encountered during compatibility testing and how they manage inventory while providing blood transfusions to patients treated with mAbs. The survey findings will help AABB to develop guidance and education programs to address these challenges.

AABB is distributing the survey to the contact person at AABB institutional member transfusion services and blood centers with managed transfusion services and IRLs. AABB encourages interested members with experience relevant to the topic to participate in the survey no later than Tuesday, Sept. 12.